When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KALA - Kala Pharmaceuticals Should Have Limited Downside With Eysuvis Now Approved
Kala Pharmaceuticals Inc.
Kala Pharmaceuticals got its second ocular therapy, Eysuvis, approved on October 27.
Peak sales estimates range from $500 million to over $1 billion due to its unique targeting of acute, episodic dry eye that is more common rather than the chronic version.
Despite this progress, Kala stock has tanked of late, creating a huge opportunity to scoop up shares of this quality company for a discount.